April 20, 2014 5:26 AM ET

Healthcare Equipment and Supplies

Company Overview of Intersect ENT Inc.

Company Overview

Sinexus, Inc., a medical device company, engages in developing therapies for ear, nose, and throat physicians in the United States. It develops a therapeutic device for the treatment of chronic sinusitis. Sinexus, Inc. was founded in 2003 and is based in Palo Alto, California.

1049 Elwell Court

Palo Alto, CA 94303

United States

Founded in 2003

Phone:

650-641-2100

Fax:

650-641-2120

Key Executives for Intersect ENT Inc.

Chief Executive Officer and President
Age: 44
Compensation as of Fiscal Year 2013.

Intersect ENT Inc. Key Developments

Intersect ENT Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-14-2014 07:30 AM

Intersect ENT Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-14-2014 07:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Lisa D. Earnhardt, Chief Executive Officer and President.

Intersect ENT Inc. Presents at MedTech Investing Conference, May-08-2013 11:35 AM

Intersect ENT Inc. Presents at MedTech Investing Conference, May-08-2013 11:35 AM. Venue: Graves 601 Hotel, 601 First Avenue North, Minneapolis, MN 55401, United States. Speakers: Lisa D. Earnhardt, Chief Executive Officer and President.

Intersect ENT Inc. Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients

Intersect ENT Inc. announced the start of RESOLVE, a prospective, randomized, blinded, multi-center clinical trial to study the use of the company's newest steroid delivery implant for patients with chronic sinusitis. Intersect ENT's new product, which is placed during a routine physician office visit, is designed as a treatment alternative for patients with recurrent sinus obstruction. Like the company's PROPEL(TM) and PROPEL(TM) mini implants used in the operating room setting to improve surgical outcomes, the product being studied releases mometasone furoate, an advanced steroid with anti-inflammatory properties, directly into the sinus lining to resolve inflammation. The product has more radial strength than the PROPEL products in order to dilate the re-obstructed sinus, and releases the steroid over a longer period of time to keep inflammation at bay. The RESOLVE Study will enroll 100 patients, at up to 20 U.S. sites, who suffer from chronic sinusitis due to recurrent sinus obstruction so severe that revision surgery is warranted. Chronic sinusitis is a condition in which patients' sinuses become swollen and inflamed, leading to difficulty breathing, facial pain or headache, and reduced sense of smell and taste. The condition is common, affecting 31 million people in the U.S., and greatly impacts quality of life. Chronic sinusitis often requires a complex combination of surgical and medical treatments. Each year, 500,000 patients undergo sinus surgery to treat the condition. Although sinus surgery is effective, majority of patients experience recurrent symptoms within the first year; as many as 25% then undergo revision surgery due to recurrent obstruction of the sinus cavity. The RESOLVE study is designed to evaluate Intersect ENT's implant in patients with polyps, which is the most challenging chronic sinusitis patient population. Polyps recur in up to 60% of patients following endoscopic sinus surgery (ESS) and are the cause for revision surgery. Co-Principal Investigators for the study are Keith D. Forwith, M.D., Ph.D. of Advanced ENT & Allergy in Louisville, KY, and Joseph Han, M.D., director of Rhinology and Endoscopic Sinus/Skull Base Surgery and professor at the Eastern Virginia Medical School.

Similar Private Companies By Industry

Company Name Region
American Medical Systems, Inc. United States
FemSuite, LLC United States
Home Care Supply, L.L.C. United States
Medica Corporation United States
St. Jude Medical, Atrial Fibrillation Division, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Intersect ENT Inc., please visit www.intersectent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.